Advanced Search


Study ID Status Title Patient Level Data
115415 Completed An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK2789869A and GSK2789868A administered in adults 21 to 64 years of age Study Listed on
115418 Completed A Phase IIIA study of immunogenicity and safety of GSK Biologicals’ quadrivalent split virion influenza vaccine FLU-Q-QIV in adults aged 18 years and older Study Listed on
115419 Completed A two part study to investigate the safety and tolerability, pharmacokinetics and pharmacodynamics of GSK2339345 in healthy subjects. Part A: an open label, dose escalating, rinse, gargle and spit study. Part B: a randomised, double-blind, placebo controlled, inhaled dose escalating study using nebulised lidocaine for blinding purposes. Study Listed on
115428 Completed A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
115429 Completed A follow-up study to evaluate the long-term persistence of GSK Biologicals’ candidate CMV vaccine administered to male adults
115433 Completed Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)
115440 Completed An open-label, randomised, replicate, six-way crossover, single dose study to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF / vilanterol (VI) inhalation powder administered via the novel dry powder inhaler. Study Listed on
115441 Completed An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects Study Listed on
115444 Completed A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers Study Listed on
115450 Completed A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric patients with previously treated chronic immune (idiopathic) thrombocytopenic purpura (ITP). PETIT2: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP
115458 Completed A Randomized, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous Ondansetron, a 5-HT3 Antagonist, on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects.
115470 Completed A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (belimumab; HGS1006) on Vaccine Responses in Subjects with Systemic Lupus Erythematosus (SLE)
115476 Completed Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients with Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET-E22-302)
115478 Completed PGx 377: Pharmacogenetic evaluation of the association of functional variation in ADRB1 and ADRB2 genes with tolerability to carvedilol in the Phase I/II study CRV110734
115484 Completed A randomized, double blind, placebo controlled study to investigate the effect of donepezil and gabapentin combination on an experimental pain model in healthy subjects
115486 Completed Tolerability and safety of multiple dose regimens of TRX4 anti-CD3 monoclonal antibody in Type 1 Diabetes Mellitus
115487 Completed Randomized, double-blind, 5 period cross over study assessing lung function in healthy volunteers following single inhalations of GSK573719 Inhalation Powder from two configurations of the Novel Dry Powder Inhaler Study Listed on
115489 Completed Special Drug Use Investigation for Arixtra® (fondaparinux) Venous Thromboembolism Treatment
115490 Completed Special Drug Use Investigation (retrospective) for Arixtra® (fondaparinux) Venous Thromboembolism Treatment (over 100kg)
115493 Terminated TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD) Study Listed on
115494 Completed Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes Study Listed on
115495 Completed Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND Study Listed on
115496 Completed DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study Study Listed on
115515 Completed An open-label single and repeat dose study to investigate the pharmacokinetic profiles of tenofovir disoproxil fumarate 300 mg in healthy Chinese subjects
115517 Completed A single/repeat dose study with three oral formulations of Firategrast (immediate release tablet, modified release tablet, and naso-gastric infusion) in healthy male volunteers



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.